Showing 2001-2010 of 18594 results for "".
Integrative Treatment of ADHD
https://reachmd.com/programs/clinicians-roundtable/integrative-treatment-of-adhd/760/Join Dr. Ari Tuckman, author of Intergrative Treatment for Adult ADHD: A Practical Easy-to Use Guide for Clinicians, as he discusses the latest integrated treatment model for Attentive Deficit/Hyperactivity Disorder.Identifying the Therapeutic Window in Dravet Syndrome: What the Envision Study Reveals About Early Disease Progression
https://reachmd.com/programs/practical-neurology/program-name/39915/Joseph Sullivan, MD, University of California, San Francisco, CA, reviews findings from the ENVISION natural history study, highlighting early neurodevelopmental changes and their implications for disease-modifying interventions in individuals diagnosed with Dravet syndrome.Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
https://reachmd.com/programs/project-oncology/dato-dxd-nsclc-tropion-lung01-data/36610/As brain metastases continue to complicate treatment decisions in advanced non-small cell lung cancer (NSCLC), recent evidence is shifting the therapeutic landscape. Data from a post-hoc analysis of TROPION-Lung01—presented at the 2025 World Conference on Lung Cancer—demonstrate meaningful intracraImproving Treatment Adherence in Pediatric Atopic Dermatitis
https://reachmd.com/programs/clinicians-roundtable/improving-treatment-adherence-in-pediatric-atopic-dermatitis/36443/Clear communication, education, and follow-up are central to managing pediatric atopic dermatitis effectively and improving treatment adherence. Discover practical strategies for working with families and optimizing care plans with Dr. Nicole Harter. Dr. Harter is an Associate Professor in the DeparProstate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
https://reachmd.com/programs/frontlines-prostate-cancer/prostate-cancer-care-testosterone-therapys-impact-on-biochemical-recurrence/32215/Recent studies have shown that testosterone therapy after radical prostatectomy does not increase—and may even reduce—the risk of biochemical recurrence in prostate cancer patients. Dive into the data and what it might mean for prostate cancer care with Dr. Mohit Khera, Professor in the Scott DepartIVUS Trial
https://reachmd.com/programs/clinicians-roundtable/ivus-trial-1/601/Implications to Patient Care and TreatmentImproving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
https://reachmd.com/programs/project-oncology/improving-diagnosis-of-castleman-disease-the-key-role-of-stromal-cells/26400/Discover how stromal cells can inform new diagnostic methods and therapeutic strategies for Castleman disease.Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
https://reachmd.com/programs/project-oncology/immune-checkpoint-inhibitors-show-promise-in-patients-with-oncogene-driver-negative-nsclc-who-have-never-smoked/33000/A multi-institutional study presented at ASCO 2025 offers critical new insights into a long-overlooked subset of non-small cell lung cancer (NSCLC) patients: never-smokers without actionable oncogenic drivers. Read about the study’s findings on the key predictors of response to immune checkpoint inhIVUS Trial
https://reachmd.com/programs/clinicians-roundtable/ivus-trial/600/Overview of the IVUS trial and resultsShared Financial Incentives for Both Physicians and Patients Improved Cholesterol Levels
https://reachmd.com/programs/the-jama-report/shared-financial-incentives-both-physicians-and-patients-improved-cholesterol-levels/7744/[Read the Article] Financial incentives for physicians or patients are one way healthcare organizations are trying to improve health outcomes. A new study examined whether providing these financial incentives would help improve low-density lipoprotein cholesterol (LDL-C) in patients with a high-risk